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Toll-like receptors (TLRs) play critical roles in innate immune defense by recognizing 
various pathogen-associated molecular patterns (PAMPs). Recent evidence suggests that in 
addition to detecting PAMPs, they can also cause sterile inflammation by reacting to 
damage-associated molecular patterns that are generated by cell injury. This is especially 
important for the TLRs that are designated to detect nucleic acids, which are also present 
within the host cells. Among these TLRs, TLR9 was initially found to sense bacterial or viral 
DNA. Upon detection of microbial DNA, TLR9 mounts a robust inflammatory response, 
including the production of inflammatory cytokines, chemokines and type I interferon (IFN). 
These cytokines in turn activate lymphocytes and the adaptive immune system important 
for eradicating the invading pathogen. Similarly, such TLR9-dependent inflammatory 
response can also be driven by non-microbial stimulant. DNA released from cell injury is 
able to stimulate TLR9 in the presence of carrier proteins. Chronic inflammation results if 
these DNA/protein complexes are not removed. Due to the role of TLR9 in regulating 
systemic inflammation, it is important to understand the detailed mechanism controlling 
TLR9 responses. Previous studies have shown that DNase II is a lysosomal DNase 
important for digesting apoptotic DNA engulfed by phagocytes, such as the macrophages. In 
the absence of DNase II, the accumulated DNA activates cytosolic DNA sensor, resulting in 
the production of a huge amount of type I IFN, which is fatal. Unexpectedly, TLR9 does not 
contribute to the inflammation in the absence of DNase II even though it senses DNA in the 
endolysosomes. These findings lead to the speculation that TLR9 does not simply respond to 
any DNA that is accumulated in the lysosome. Instead, DNase II may be needed in DNA 
sensing by TLR9. In the present study, the role of DNase II in TLR9 responses was 
investigated. We found that in murine bone marrow-derived conventional dendritic cells 
(BM-cDCs) and plasmacytoid dendritic cells (BM-pDCs), DNase II was indispensable for 
TLR9 to mount an inflammatory response towards one of its best-known ligands, CpG-A, 
but not for its another ligand, the CpG-B. Type I IFN production triggered by CpG-A in 
BM-pDCs also required DNase II. The ability of DNase II in facilitating TLR9 responses was 
found to be dependent on its DNase activity. DNase II digested CpG-A (a 20-mer) into 
shorter fragments of around 11-12 nucleotides in length. CpG-A harbors a central 
palindrome and a poly-G tail which enable the oligo to form nanoparticles in physiological 
conditions. It is this natural conformation of CpG-A that enable a potent induction of IFN. 
As the central palindrome is nuclease-sensitive, DNase II was likely to cleave the central 
region of CpG-A to generate the short fragments. Therefore, truncated CpG-A fragments 
were made in an attempt to mimic the product after cleavage by DNase II. Out of the 
truncated fragments examined, one of them (named A3’11) was found to stimulate TLR9 
even in the absence of DNase II. To examine the localization of DNase II, monoclonal 
antibodies (mAbs) recognizing the endogenous murine DNase II were established. The 
literature suggests that DNase II resides in lysosome for DNA digestion, however, using the 
mAbs, it was found that in addition to the LAMP2-positive lysosome, a more significant 
amount of DNase II was localized in wheat germ agglutinin (WGA)-positive vesicles, a 
marker for the trans-Golgi. However, upon CpG-A stimulation, DNase II recruitment to the 
LAMP2-positive lysosomes was dramatically enhanced. This was not observed after CpG-B 
or the A3’11 oligodeoxynucleotide stimulation. These results affirm the notion that DNase II 
was required in TLR9-mediated CpG-A responses by generating a short DNA fragment 
stimulatory to TLR9 in lysosomal compartments. Since CpG-A is also widely used as an 
adjuvant in anti-tumor or anti-viral vaccines, as well as in treating certain diseases, 
understanding the role of DNase II in CpG-A responses would contribute to novel vaccine 
design and treatments in the future.  
